Lightnews — Scholar-powered news

Reposted by Roberto Borea MD

International Society of Liquid Biopsy @islb.info · May 31

🩸🚀 New Insights in Liquid Biopsy! 🧬

The ISLB has just published a perspective article about Minimal requirement for ctDNA analysis.

🔗 Read the full article here
www.journalofliquidbiopsy.com/article/S295...

International Society of Liquid Biopsy (ISLB) perspective on minimal requirements for ctDNA testing in solid tumors

Circulating tumor DNA (ctDNA) testing has transformed precision oncology by enabling the non-invasive detection of actionable mutations. To facilitate broader clinical adoption and improve testing acc...

www.journalofliquidbiopsy.com

3 4

Roberto Borea MD @robertoboreamd.bsky.social · May 27

🚨Excited to represent the @islb.info at #ASCO25!

Swing by our booth, we’re ready to talk about #LiquidBiopsy and opportunities!
Got questions about the society? We’ve got answers. Come to connect!🩸

@ascocancer.bsky.social @christianrolfo.bsky.social @rolfolab.bsky.social

3 6

Roberto Borea MD @robertoboreamd.bsky.social · May 19

#TME in #NSCLC shapes therapy resistance and progression

- a tumor can have two immune niches: rich and poor
- more than immune cells: CAFs, TAMs, DCs, T, NK..
- patient-specific determinants modulate the TME

🔍emerging technologies

www.nature.com/articles/s41...

3

Reposted by Roberto Borea MD

Yvonne Diaz @yvonnediaz.bsky.social · May 18

Promising signals from the ALEK-B ph 2 trial: combining alectinib w bevacizumab achieved 97.1% 12-mo PFS & median PFS of 39.6 months in ALK+ #NSCLC. Intracranial control also notably strong.

Could this combo help overcome resistance in more aggressive ALK variants?
#research #lungcancer

3 8

Roberto Borea MD @robertoboreamd.bsky.social · May 19

💡Final #CHRYSALIS trials results: #Amivantamab delivers durable responses in #METex14 #NSCLC, even after MET TKI failure.

Overall population:
- ORR 32%
- CBR 69%
- median DoR 11.2 mo

48% asian, 39% white.
9% discontinued due to side effects

@oncoalert.bsky.social

1 1

Roberto Borea MD @robertoboreamd.bsky.social · May 14

📰EGFR-TKI resistance in LUAD isn’t always genetic.
- 39 pts-derived organoids
- 50% resistant organoids had no know res mutations. A “basal-shift” phenotype drives res via NKX2-1 loss.
- Knockout of NKX2-1 → basal-shift + Osim res
- These tumors often lose CDKN2A/B

pbs.twimg.com/media/Gq6QwX...

Reposted by Roberto Borea MD

Christian Rolfo @christianrolfo.bsky.social · May 12

Very honored of this important recognition in my born country. Blessed to share this special moment with my family, friends and great colleagues from Argentina 🇦🇷 looking forward to continue working with @UBAonline from OSU @OhioStateMedOnc ! Thanks to all my team @rolfolab.bsky.social

5 2 12

Roberto Borea MD @robertoboreamd.bsky.social · May 5

🔬📈 Check out our new commentary on Selinexor (an XPO1 inhibitor) + ICIs in uveal melanoma patients in a phase  1B trial!
➡️12m OS 55 % 
➡️0 % ORR
➡️manageable safety profile
@christianrolfo.bsky.social @rolfolab.bsky.social @oncoalert.bsky.social #CarlosAyala

pmc.ncbi.nlm.nih.gov/articles/PMC...

Selinexor in Uveal Melanoma: A Hopeful Step or Just Another Hurdle?

pmc.ncbi.nlm.nih.gov

2 2

Reposted by Roberto Borea MD

RolfoLab @rolfolab.bsky.social · May 5

New research from the #VISION trial of #tepotinib in #NSCLC with #METex14 skipping highlights key differences when patients are identified by LBxvs TBx.
➡️ #Tepotinib showed robust efficacy regardless of biopsy type
@christianrolfo.bsky.social @oncoalert.bsky.social

4 3 3

Reposted by Roberto Borea MD

RolfoLab @rolfolab.bsky.social · Apr 26

Visit at #AACR25 the poster by Dr. Eswar Shankar on “Synergistic Inhibition of TNBC via EZH2 inhibition and D1 Receptor Agonism”
@OSUCCC_James

@osuwexmed.bsky.social
@christianrolfo.bsky.social
@theaacr.bsky.social
pbs.twimg.com/media/Gpay9i...

1 6

Roberto Borea MD @robertoboreamd.bsky.social · Apr 21

Super excited to share the review I wrote with Carolina Reduzzi published in the Journal of Liquid Biopsy on the transformative impact of LB in oncology! 🩸🔬

LB is reshaping cancer care 💥
Check it out 👉 pubmed.ncbi.nlm.nih.gov/40255897/

@islb.info @christianrolfo.bsky.social @rolfolab.bsky.social

3 7

Reposted by Roberto Borea MD

Christian Rolfo @christianrolfo.bsky.social · Apr 11

Congrats Roberto! And welcome to @rolfolab.bsky.social !!!

Roberto Borea MD @robertoboreamd.bsky.social · Apr 11

Honored to be here at hashtag #TexasLung25 in #Austin as one of the 10 winners of the poster competition 🏅

Grateful for the chance to meet with exceptional people 👐

@stephenvliu.bsky.social @tinacascone @christianrolfo.bsky.social

2 2

Roberto Borea MD @robertoboreamd.bsky.social · Apr 12

Day 3 at #TexasLung25 diving into diagnostics, #MRD, and #LiquidBiopsy with an outstanding faculty! 🩸🔬

Learning from the best: @christianrolfo.bsky.social @davidgandera @WadeIams @osucccjames.bsky.social @rolfolab.bsky.social

Exciting discussions shaping the future of #lungcancer testing! 📚

2 4

Roberto Borea MD @robertoboreamd.bsky.social · Apr 11

Honored to be here at hashtag #TexasLung25 in #Austin as one of the 10 winners of the poster competition 🏅

Grateful for the chance to meet with exceptional people 👐

@stephenvliu.bsky.social @tinacascone @christianrolfo.bsky.social

1 6

Roberto Borea MD @robertoboreamd.bsky.social · Mar 27

As always, an insightful presentation by @UmbertoMalapelle

➡️ "From single gene testing to CGP." 🔬✨
at #ELCC25 @myesmo.bsky.social

We must continue this path to improve treatment selection!

@islb.info #precisiononcology #lungcancer

⬇️ Key message

1 3

Roberto Borea MD @robertoboreamd.bsky.social · Mar 25

Today, I had the pleasure of presenting to the @MtSinaiASCOOSIG on the role of #liquidbiopsy in clinical practice and #precisiononcology! ❤️ An incredibly dynamic and engaging group! Great discussions and insights!

@osucccjames.bsky.social @rolfolab.bsky.social @christianrolfo.bsky.social
@unige

1 3

Roberto Borea MD @robertoboreamd.bsky.social · Mar 19

📢 5-year outcomes from EMPOWER-Lung 1: 1L cemiplimab vs chemo in PD-L1 high (≥50%) NSCLC!

👫🏻 565 pts; 1 vs 1
✅ mOS favors cemiplimab: 26.1 vs 13.3m (HR 0.59), 38.8m in PD-L1 ≥90%
✅ PFS 8.1 vs 5.3m (HR 0.50)
✅ 5y OS rate: 29% vs 15%

www.jto.org/article/S155...

#Immunotherapy #NSCLC

Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC with PD-L1 Expression ≥50%: 5-Year Outcomes of EMPOWER-Lung 1

Earlier results from the phase 3 EMPOWER-Lung 1 trial demonstrated significant survival benefits and a generally acceptable safety profile of first-line cemiplimab monotherapy versus chemotherapy for ...

www.jto.org

1 4

Roberto Borea MD @robertoboreamd.bsky.social · Mar 18

What a great news! Finally we have a journal dedicated to liquid biopsy research! I am truly excited. 🔥

International Society of Liquid Biopsy @islb.info · Mar 18

🎉🩸 Thrilled to share that the Journal of Liquid Biopsy is now officially live in PubMed and PMC! A significant step forward for JLB

Check it out here: pmc.ncbi.nlm.nih.gov/journals/?te...

#LiquidBiopsy #PubMed @christianrolfo.bsky.social @yukselurun.bsky.social @eloisajantus.bsky.social

1 2

Reposted by Roberto Borea MD

International Society of Liquid Biopsy @islb.info · Mar 18

📢 Exciting update in the field of liquid biopsy! A new editorial highlights the essential role of the International Society of Liquid Biopsy (ISLB) in establishing quality framework for LB clinical implementation. 🧬🩸
Read more: doi.org/10.1016/j.crit…#LiquidBiopsysy
@christianrolfo.bsky.social

5 5

Roberto Borea MD @robertoboreamd.bsky.social · Mar 17

🚨 Out in @natrevclinoncol.bsky.social

📌ctDNA helps uncover resistance mechanisms
📌Standardized protocols are crucial for improving applications
📌ctDNA + tissue provides a more comprehensive view

nature.com/articles/s41...

@christianrolfo.bsky.social @osucccjames.bsky.social

2 6

Roberto Borea MD @robertoboreamd.bsky.social · Mar 14

Now you can find the link to complete our @islb.info survey in the @oncoalert.bsky.social newsletter! 📨

It only takes 5 min to help us understand how LB 🩸 is reshaping clinical practice worldwide!

bit.ly/43JzN03

@christianrolfo.bsky.social @rolfolab.bsky.social @weoncologists.bsky.social

4 6

Roberto Borea MD @robertoboreamd.bsky.social · Mar 13

Diving into the latest on #METex14 skipping #NSCLC, from testing to treatment, with an outstanding panel of experts! 🌟🔬
--> bit.ly/3DFSzLi
Panelists:
@christianrolfo.bsky.social
#UmbertoMalapelle
#YasushiYatabe
#MervatMahrous
Organizer:
#touchOncology

@rolfolab.bsky.social @oncoalert.bsky.social

2 5

Roberto Borea MD @robertoboreamd.bsky.social · Mar 12

Honored to be among the winners of the #TexasLung25 Poster Competition! 🎉 Grateful for the opportunity to share my research and contribute to the future of #lungcancer!
@christianrolfo.bsky.social @rolfolab.bsky.social @stephenvliu.bsky.social @osucccjames.bsky.social

➡️ hubs.la/Q03bqnlB0

5

Roberto Borea MD @robertoboreamd.bsky.social · Mar 11

The HER2 protein is becoming a crucial target not only in breast cancer but also in other tumor subtypes. 🔬✨ Super experts discuss the role of IHC in #lungcancer and #ovariancancer!

@christianrolfo.bsky.social @rolfolab.bsky.social
@osucccjames.bsky.social
#HER2 #IHC #Targettherapy

The OncoAlert Network 🚨 @oncoalert.bsky.social · Mar 10

JOIN US for a discussion on HER2🧬testing & evolving role of IHC🔬 in hashtag#LungCancer & hashtag#OvarianCancer

REGISTER HERE👇👇
buff.ly/7F6ztd4

JOIN US TUESDAY MARCH 11, 2025

4 8

Roberto Borea MD @robertoboreamd.bsky.social · Mar 5

✨ Insightful presentation by @manelesteller.bsky.social from
@carrerasijc.bsky.social at @osuwexmed.bsky.social
Starting from #epigenetics to #spatialtranscriptomics, unlocking a deeper understanding of tumor biology and cancer treatment! 🔬🧬💊
@christianrolfo.bsky.social @rolfolab.bsky.social

2 3